Medacta Group SA

Medacta Group SA reported H1 2026 revenue of EUR368 million, up almost 10% at constant currency, with adjusted EBITDA of EUR97 million and a 27.8% margin at constant currency. Net profit came in at EUR42 million, or 11.4% of revenue, while adjusted comparable net profit was EUR49 million versus EUR46 million a year earlier. Gross margin fell to 65.2% from 68.3% on adverse FX, price erosion and unfavorable geographic and product mix, and free cash flow was negative EUR18.6 million as operating cash flow slipped to about EUR56 million from EUR73 million. Regionally, EMEA grew 10%, APAC 13.1%, Latin America 16.4% and North America 7%, while Spine grew just 4.5% amid a strategic refocus on enabling technology and direct sales. Medacta confirmed its 2026 outlook for revenue growth of 10% to 14% and adjusted EBITDA margin expansion of around 50 basis points at constant currency, alongside a midterm revenue CAGR of 12% to 15%.